Radotinib (IY-5511)是一种口服、脑渗透性的选择性Bcr-Abl1抑制剂,具有抗肿瘤与抗朊病毒活性。它通过抑制细胞增殖、诱导细胞周期阻滞与凋亡发挥作用,可用于慢性髓细胞白血病、多发性骨髓瘤及朊病毒病等的研究。
|
英文别名 (English Synonym) |
Radotinib (IY-5511) |
|
中文名称 (Chinese Name) |
雷度替尼 |
|
靶点 (Target) |
Bcl-2 Family |
|
通路 (Pathway) |
Apoptosis |
|
CAS号 (CAS NO.) |
926037-48-1 |
|
分子式 (Formula) |
C27H21F3N8O |
|
分子量 (Molecular Weight) |
530.5 |
|
纯度 (Purity) |
≥98% |
|
溶解性 (Solubility) |
溶于DMSO |
-25~-15℃保存，有效期3年
[1] Heo SK, Noh EK, Seo HJ, Lee YJ, Koh S, Min YJ, Choi Y, Jo JC. Radotinib inhibits multiple myeloma cell proliferation via suppression of STAT3 signaling. PLoS One. 2022 May 3,17(5):e0265958. doi: 10.1371/journal.pone.0265958. PMID: 35503759, PMCID: PMC9064077.[2]Choi YG, Jang B, Park JH, Choi MW, Lee GY, Cho DJ, Kim HY, Lim HK, Lee WJ, Choi EK, Kim YS. Radotinib Decreases Prion Propagation and Prolongs Survival Times in Models of Prion Disease. Int J Mol Sci. 2023 Jul 31,24(15):12241. doi: 10.3390/ijms241512241. PMID: 37569615, PMCID: PMC10419185.
